A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 26, 2015. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm's website at http://www.rosenlegal.com/cases-299.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) securities from March 8, 2013 through August 20, 2015, all dates inclusive (the "Class Period") of the important October 26, 2015 lead plaintiff deadline. The lawsuit seeks to recover damages for Northwest Biotherapeutics, Inc. investors under the federal securities laws. To join the Northwest Biotherapeutics, Inc. class action, go to the firm's website at http://www.rosenlegal.com/cases-299.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action. The lawsuit is pending in U.S. District Court for the District of Maryland. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Northwest Biotherapeutics' claims concerning positive results from its DCVax-Direct Trial were based on preliminary and unverified trial results; (2) the DCVax-Direct Trial results on which Northwest Biotherapeutics reported had not been assessed or examined by the hospitals conducting the trials; (3) Northwest Biotherapeutics' statements about DCVax-Direct were derived from patient case report forms that the hospitals were obliged to send to Northwest Biotherapeutics only because it sponsored the study; (4) Northwest Biotherapeutics was the subject of an aggressive stock promotion campaign which included promoters using fictitious identities and false credentials; (5) German regulators required additional information from Northwest Biotherapeutics so that the DCVax-L Trial could continue uninterrupted; and (6) consequently, Northwest Biotherapeutics' financial statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.